CombiMatrix Corp, Mukilteo, Wash, and Clarient, Inc, Aliso Viejo, Calif, have partnered for HemeScan, a genomics-based cancer test for the treatment and care of chronic lymphocytic leukemia (CLL), and other cancers.
In a single test, it assays the genomic loci for copy number aberrations currently measured by commercial multi-probe fluorescent in situ hybridization kits.
The test was developed by CombiMatrix and validated in collaboration with a team of academic centers, such as the MD Anderson Cancer Center in Houston, the University of Texas Health Science Center in San Antonio, and Netherlands Cancer Institute in Amsterdam.
In addition to CLL, the test has been clinically validated for acute lymphoblastic leukemia (ALL: 48.62, -0.80, -1.61%) and myelodysplastic syndrome (MDS: 17.19, -0.69, -3.85%), and it is being tested for multiple myeloma (MM: 51.14, +0.29, +0.57%).
CLL is the most common form of the B-cell lineage lymphoproliferative disorders, accounting for about 30% of all cases in the United States and Europe. More than 10,000 new cases are found annually nationwide, and more than 150,000 patients are living with the disease. CLL is a clinically heterogeneous disorder with defined risk groups associated with a full spectrum of patient prognostic outcomes.
CombiMatrix is a biotechnology company that develops and sells proprietary technologies and products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, defense, and homeland security.
